A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06691906
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.

Key Dates

Start date
Mar 18, 2024
Status verified
Nov 2024
Primary completion
May 1, 2024
Completion
May 1, 2024

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Enlicitide Decanoate Treatment A
    Participants will receive a single dose of enlicitide decanoate formulation 1 on Day 1 on an empty stomach.
  • Experimental: Enlicitide Decanoate Treatment B
    Participants will receive a single dose of enlicitide decanoate formulation 2 on Day 1 on an empty stomach.

Primary Outcome Measure

Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of enlicitide decanoate [ Time Frame: Predose and at designated timepoints (up to 24 hours postdose) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion (Site 0001)LincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies